Previously, we demonstrated that supplementation of resuscitation fluids with the Kv7 voltage-activated potassium channel inhibitor linopirdine reduces fluid resuscitation requirements and stabilizes hemodynamics in various rat models of hemorrhagic shock. To further evaluate the therapeutic potential of linopirdine, we tested the effects of linopirdine-supplemented resuscitation fluids in a rat model of ischemia-reperfusion injury-induced acute respiratory distress syndrome (ARDS). Ventilated rats underwent unilateral lung ischemia from t=0-75 min, followed by lung reperfusion and fluid resuscitation to a mean arterial blood pressure of 60 mmHg with normal saline (NS, n=9) or NS supplemented with 50 µg/ml linopridine (NS-L), n=7) until t=360 min. As compared with NS, fluid resuscitation with NS-L stabilized blood pressure and reduced fluid requirements by 40% (p<0.05 vs. NS at t=240-360 min). While NS-L did not affect ARDS development, it reduced mortality from 66% with NS to 14% with NS-L (p=0.03, hazard ratio 0.14; 95% confidence interval of the hazard ratio: 0.03-0.65). Median survival time was 240 min with NS and >360 min with NS-L. As compared with NS treated animals that survived the observation period (n=3), however, plasma lactate and creatinine concentrations at t=360 min were higher with NS-L (n=6; p<0.05). Our findings extend therapeutic potential of NS-L from hypovolemic/hemorrhagic shock to hemodynamic instability under normovolemic conditions during organ ischemia-reperfusion injury. Possible adverse effects of NS-L, such as impairment of renal function and/or organ hypoperfusion, require further evaluation in long-term pre-clinical models.

Department of Surgery Loyola University Chicago Stritch School of Medicine Maywood IL USA

Zobrazit více v PubMed

BABU FS, LIANG X, ENTEN GA, DESANTIS AJ, VOLKMAN BF, GAO X, MAJETSCHAK M. Natural and engineered chemokine (C-X-C motif) receptor 4 agonists prevent acute respiratory distress syndrome after lung ischemia-reperfusion injury and hemorrhage. Sci Rep. 2020;10:11359. doi: 10.1038/s41598-020-68425-0. PubMed DOI PMC

BYRON KL, BRUEGGEMANN LI. Kv7 potassium channels as signal transduction intermediates in the control of microvascular tone. Microcirculation. 2018;25 doi: 10.1111/micc.12419. PubMed DOI

FAULKNER MA, BURKE RA. Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel. Expert Opin Drug Saf. 2013;12:847–855. doi: 10.1517/14740338.2013.823399. PubMed DOI

HAICK JM, BYRON KL. Novel treatment strategies for smooth muscle disorders: Targeting Kv7 potassium channels. Pharmacol Ther. 2016 doi: 10.1016/j.pharmthera.2016.05.002. PubMed DOI

HARISH S, BHUVANA K, BENGALORKAR GM, KUMAR T. Flupirtine: Clinical pharmacology. J Anaesthesiol Clin Pharmacol. 2012;28:172–177. doi: 10.4103/0970-9185.94833. PubMed DOI PMC

MACKIE AR, BYRON KL. Cardiovascular KCNQ (Kv7) potassium channels: physiological regulators and new targets for therapeutic intervention. Mol Pharmacol. 2008;74:1171–1179. doi: 10.1124/mol.108.049825. PubMed DOI

MICELI F, SOLDOVIERI MV, MARTIRE M, TAGLIALATELA M. Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs. Curr Opin Pharmacol. 2008;8:65–74. doi: 10.1016/j.coph.2007.10.003. PubMed DOI

NASSOIY SP, BABU FS, LAPORTE HM, BYRON KL, MAJETSCHAK M. Effects of the Kv7 voltage-activated potassium channel inhibitor linopirdine in rat models of haemorrhagic shock. Clin Exp Pharmacol Physiol. 2018 doi: 10.1111/1440-1681.12958. PubMed DOI PMC

NASSOIY SP, BYRON KL, MAJETSCHAK M. Kv7 voltage-activated potassium channel inhibitors reduce fluid resuscitation requirements after hemorrhagic shock in rats. J Biomed Sci. 2017;24:8. doi: 10.1186/s12929-017-0316-1. PubMed DOI PMC

PIERRAKOS C, VINCENT JL. The changing pattern of acute respiratory distress syndrome over time: a comparison of two periods. Eur Respir J. 2012;40:589–595. doi: 10.1183/09031936.00130511. PubMed DOI

SALOMONSSON M, BRASEN JC, BRAUNSTEIN TH, HAGELQVIST P, HOLSTEIN-RATHLOU NH, SORENSEN CM. K(V)7. channels participate in the control of rodent renal vascular resting tone. Acta Physiol (Oxf) 2015;214:402–414. doi: 10.1111/apha.12525. PubMed DOI

STOTT JB, JEPPS TA, GREENWOOD IA. K(V)7 potassium channels: a new therapeutic target in smooth muscle disorders. Drug Discov Today. 2014;19:413–424. doi: 10.1016/j.drudis.2013.12.003. PubMed DOI

WULFF H, CASTLE NA, PARDO LA. Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov. 2009;8:982–1001. doi: 10.1038/nrd2983. PubMed DOI PMC

Inhibition of extracellular signal-regulated kinase downregulates endoplasmic reticulum stress-induced apoptosis and decreases brain injury in a cardiac arrest rat model